Table 2 Characteristics of patients with ovarian carcinoma according to bevacizumab administration

Age (years)

0.07

Median (range)

54

(30–77)

61

(29–77)

FIGO stage (%)

0.03

 I

2

(4.5)

7

(21.2)

 II

4

(9.1)

3

(9.1)

 III

33

(75.0)

15

(45.5)

 IV

5

(11.4)

8

(24.2)

Histological types (%)

0.24

 Serous carcinoma

26

(59.1)

18

(54.6)

 Clear cell carcinoma

5

(11.4)

9

(27.3)

 Endometrioid carcinoma

6

(13.6)

1

(3.0)

 Carcinosarcoma

1

(2.3)

1

(3.0)

 Squamous cell carcinoma

1

(2.3)

0

(0)

 Mucinous carcinoma

0

(0)

1

(3.0)

 Adenocarcinoma not otherwise specified

5

(11.4)

3

(9.1)

Residual tumor (≥ 1 cm) at primary surgery (%)

0.08

 Yes

22

(50.0)

10

(30.3)

 No

22

(50.0)

23

(69.7)

Prior chemotherapy regimens before bevacizumab-containing regimens (times)

3.8

(1–11)

3.5

(1–11)

0.61

Total dose of bevacizumab set for the first time during the first cycle (mg)

400.0

(400)

745.6

(520–1113)

 < 0.01

Best response

0.13

 Complete remission

3

(6.8)

0

(0)

 Partial remission

6

(13.6)

6

(18.2)

 Stable disease

27

(61.4)

15

(45.5)

 Progressive disease

8

(18.2)

12

(36.4)

Response rate (%)

20

18.2

0.52

Clinical benefit rate (%)

82

63.6

0.07

Stable duration (months)

8

(0–37)

5

(0–10)

 < 0.01